Biodesix (BDSX) Operating Income (2019 - 2026)

Biodesix (BDSX) has 8 years of Operating Income data on file, last reported at -$6.2 million in Q1 2026.

• Quarterly Operating Income rose 32.13% year-over-year to -$6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.9 million (up 23.53% YoY) and the FY2025 annual result came in at -$27.9 million, up 19.2% from the prior year.
• Operating Income fell to -$6.2 million in Q1 2026, from -$2.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$2.0 million in Q4 2025 to a low of -$16.4 million in Q1 2023.
• A 5-year average of -$9.4 million and a median of -$9.1 million in 2025 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2022 — Operating Income tumbled 159.02% — and 2025, when it soared 70.42%.
• Tracing BDSX's Operating Income over 5 years: stood at -$13.9 million in 2022, then surged by 50.54% to -$6.9 million in 2023, then climbed by 3.22% to -$6.6 million in 2024, then soared by 70.42% to -$2.0 million in 2025, then tumbled by 215.25% to -$6.2 million in 2026.
• The last three Operating Income figures came in at -$6.2 million (Q1 2026), -$2.0 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.